7KFZ image
Entry Detail
PDB ID:
7KFZ
EMDB ID:
Title:
Structure of a ternary KRas(G13D)-SOS complex
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2020-10-15
Release Date:
2021-03-31
Method Details:
Experimental Method:
Resolution:
3.47 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:GTPase KRas
Mutations:G13D
Chain IDs:A, C
Chain Length:170
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Son of sevenless homolog 1
Chain IDs:B
Chain Length:491
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Molecular assemblies of the catalytic domain of SOS with KRas and oncogenic mutants.
Proc.Natl.Acad.Sci.USA 118 ? ? (2021)
PMID: 33723061 DOI: 10.1073/pnas.2022403118

Abstact

Ras is regulated by a specific guanine nucleotide exchange factor Son of Sevenless (SOS), which facilitates the exchange of inactive, GDP-bound Ras with GTP. The catalytic activity of SOS is also allosterically modulated by an active Ras (Ras-GTP). However, it remains poorly understood how oncogenic Ras mutants interact with SOS and modulate its activity. Here, native ion mobility-mass spectrometry is employed to monitor the assembly of the catalytic domain of SOS (SOScat) with KRas and three cancer-associated mutants (G12C, G13D, and Q61H), leading to the discovery of different molecular assemblies and distinct conformers of SOScat engaging KRas. We also find KRasG13D exhibits high affinity for SOScat and is a potent allosteric modulator of its activity. A structure of the KRasG13D•SOScat complex was determined using cryogenic electron microscopy providing insight into the enhanced affinity of the mutant protein. In addition, we find that KRasG13D-GTP can allosterically increase the nucleotide exchange rate of KRas at the active site more than twofold compared to KRas-GTP. Furthermore, small-molecule Ras•SOS disruptors fail to dissociate KRasG13D•SOScat complexes, underscoring the need for more potent disruptors. Taken together, a better understanding of the interaction between oncogenic Ras mutants and SOS will provide avenues for improved therapeutic interventions.

Legend

Protein

Chemical

Disease

Primary Citation of related structures